Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takara Bio Obtains License from Kyoto Univ.
April 20, 2009
- Eli Lilly Licenses Cialis to Nippon Shinyaku
April 20, 2009
- GE, Intel Ally in Home Health Technologies
April 20, 2009
- Otsuka, BMS Extend Agreement on Abilify, Embark on Global Oncology Collaboration
April 20, 2009
- REGULATORY NEWS IN BRIEF
April 13, 2009
- MediciNova to Suspend All Negotiations on MN-166 for MS
April 13, 2009
- Points of Discussion on Online Sale of Drugs Listed
April 13, 2009
- Taiho Licenses Yondelis from PharmaMar
April 13, 2009
- NEW PRODUCTS
April 13, 2009
- Daiichi Sankyo to Place Top Priority on Class-1 Products
April 13, 2009
- Eisai Licenses Urief from Kissei in ASEAN Countries, India
April 13, 2009
- BUSINESS NEWS IN BRIEF
April 13, 2009
- NEW PRODUCTS
April 13, 2009
- Mochida Aims at ¥84.5 Bil. Sales in FY2011
April 13, 2009
- Actavis ASKA Aims at Sales of ¥10 Bil. by 2015
April 13, 2009
- JKMA Publishes English Terminology for Kampo Medicines
April 13, 2009
- Co-DIO, Ecard Jump to 1st and 2nd Place on GP Market: Rep Track Survey
April 13, 2009
- 22 Companies to Apply for NHI Price Listing for Generics of Cravit
April 13, 2009
- Council to Focus on Differences in Prices of Medical Devices in Japan and Abroad
April 13, 2009
- Pharmacists Hold Key to Promotion of the Use of Generics: Mr Isobe
April 13, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…